Company
Crossject SA
Headquarters: Dijon, France
Employees: 85
CEO: Mr. Patrick Alexandre
Market Cap
€85.3 Million
EUR as of July 1, 2025
US$100.7 Million
Crossject SA Categories
France Healthcare Medical Instruments & SuppliesFrance Healthcare France Medical Instruments & Supplies
Top Competitors by Market Capitalization
Industry: Medical Instruments & Supplies
| Company | Market Cap (USD) |
|---|---|
| Intuitive | $193.76 B |
| EssilorLuxottica SA | $128.90 B |
| Becton, Dickinson and Company | $50.81 B |
| Alcon Inc. | $44.33 B |
| HOYA Corp | $40.30 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Stocks & Indices
Crossject SA has the following listings and related stock indices.
Stock: Euronext: ALCJ wb_incandescent
Stock: FSX: 74C wb_incandescent